Brief: Abbott's Cologuard Plus Receives CE Mark For Colorectal Cancer Screening In Europe
20/10/2026 07:19
BRIEF-Abbott's Cologuard Plus Receives CE Mark For Colorectal Cancer Screening In Europe Oct 20 (Reuters) - Abbott Laboratories ABT.N:
ABBOTT'S COLOGUARD PLUS® RECEIVES CE MARK FOR COLORECTAL CANCER SCREENING IN EUROPE
Source text: ID:nPrev1QXRa
Further company coverage: ABT.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Abbott Laboratories
See all newsBrief: Abbott Announces Availability Of Panbio Covid-19/Flu A&B Self-Test In Canada
Perrigo to sell infant formula business to MeridianMade for up to $175 million
Brief: Abbott Initiates Pivotal Trial For Cephea™ Device, An Innovative Treatment For Mitral Heart Valve Disease
Corrected: German startup NVision shows new path to quantum computing chips in Nature paper
Brief: Abbott Receives FDA Approval For First Device To Treat Leaks After Heart Valve Replacement